{
  "event_id": "d860a2f18b22",
  "ticker": "SGEN",
  "company_name": "Seagen",
  "drug_name": "PADCEV & KEYTRUDA",
  "pdufa_date": "20221028",
  "approval_type": {
    "status": "found",
    "value": "bla",
    "source": "websearch:EV-302/KEYNOTE-A39 Phase 3",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.921018",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Urothelial cancer (+KEYTRUDA combo)",
    "source": "websearch:EV-302/KEYNOTE-A39 Phase 3",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.921020",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "enfortumab vedotin",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:39:43.834535",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Oncology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:59.075173",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:39:43.834535",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:EV-302/KEYNOTE-A39 Phase 3",
    "confidence": 0.95,
    "evidence": [
      "EV-302/KEYNOTE-A39 Phase 3"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.921005",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "<0.0001",
    "source": "websearch:EV-302/KEYNOTE-A39 Phase 3",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.921012",
    "error": null
  },
  "p_value_numeric": 0.0001,
  "effect_size": {
    "status": "found",
    "value": "OS: HR 0.51 (49% RRR), 33.8 vs 15.9 mo; PFS: HR 0.48",
    "source": "websearch:EV-302/KEYNOTE-A39 Phase 3",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.921015",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group"
  ],
  "nct_ids": [
    "NCT02362594"
  ],
  "enrollment": {
    "count": 1019,
    "type": "ACTUAL",
    "nct_id": "NCT02362594",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:30:27.588128"
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:29:22.688769",
  "enriched_at": "2026-01-11T20:15:44.060696",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "d55ff03e2059",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": false,
    "accelerated_approval": true
  },
  "mechanism_of_action": "PD-1 inhibitor",
  "adcom_info": {
    "scheduled": true,
    "held": true,
    "outcome": "favorable",
    "vote": "positive"
  },
  "days_to_pdufa": -1170,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:42.051892",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:11.222199"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:11.222207"
  },
  "breakthrough_therapy": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA Grants Priority Review for Supplemental Biologics License ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:15:31.677602",
    "search_status": "FOUND"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FF-10832 Granted FDA Orphan Drug Designation for the ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:15:35.058235",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA Grants Priority Review for KEYTRUDA ... - Merck"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:15:36.218738",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:15:42.686520",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA Approves Keytruda and Padcev for Muscle Invasive Bladder ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:15:44.060685",
    "search_status": "FOUND"
  }
}